Company: Denali Therapeutics Inc
Symbol: DNLI
Description: Their goal is to discover and develop therapeutics to defeat degeneration.
Shares: 8.33 million
Price Range: $17.00-$19.00
Trade Date: 12/8
Underwriter(s): Goldman Sachs, J.P. Morgan, Morgan Stanley
Co-Manager(s): Evercore ISI
Filed: 11-27-17
Business: Their total portfolio currently consists of eleven programs. To prioritize the allocation of their resources, they designate certain programs as core programs and others as seed programs, and they currently have six core programs and five seed programs. Their core programs are at various stages of clinical and preclinical development. Their most advanced core programs are their LRRK2 inhibitor program to address Parkinson’s disease and their RIPK1 inhibitor program to address Alzheimer’s disease and ALS. The two most advanced product candidates in their LRRK2 program, DNL201 and DNL151, are potent, selective and brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson’s disease. DNL201 is currently in a Phase 1 clinical trial in healthy volunteers in the United States. DNL151 has completed IND-enabling preclinical studies. They submitted a CTA for DNL151 to the Netherlands Health Authority in October 2017 and it was accepted in November 2017. The most advanced product candidate in their RIPK1 inhibitor program, DNL747, is a potent, selective and brain penetrant small molecule RIPK1 inhibitor product candidate for ALS and Alzheimer’s disease. DNL747 is in IND-enabling preclinical studies and they plan to submit a CTA in early 2018.
Insider Buying: Certain of their existing shareholders, including certain of their directors and affiliates of their directors, and their affiliated entities have indicated an interest in purchasing an aggregate of up to approximately $50.0 million of their common shares in this offering at the initial public offering price per share.
Book-Building Status: The way the book comes together during the week of the roadshow is the most critical indicator to first-day and first-week performance. IPO Boutique uses its 45 years of experience and sources all over the street to gather daily subscription levels, specific price guidance and what type of investors are currently in the book or are anchoring orders in the book. In addition, recent underwriter performance on sector specific deals is a strong factor that IPO Boutique takes into account when determining if our clients should indicate for any offering.
IPO Boutique subscription clients receive daily updates on this critical information.
Conclusion: IPO Boutique provides ratings, daily commentary and a forecast for how this IPO will open vs. its offering price. We have kept a track record with our performance for last 12 years at our website.
Indicate with confidence, SUBSCRIBE today.
English
Arabic
Chinese (Simplified)
Dutch
French
German
Italian
Portuguese
Russian
Spanish